Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of elvitegravir
Drug 1
Drug 1 dose
150 mg elvitegravir / 150 mg cobicistat once daily
Drug 1 effect
Cmax decreased 45%, AUC decreased 69%, Cmin decreased 97%
Drug 2
Drug 2 dose
200 mg BID
Drug 2 effect
Cmax increased 40%, AUC increased 43%, Cmin increased 51%. Epoxide metabolite (pharmacologically active) Cmax decreased 73%, AUC decreased 35%, and Cmin decreased 41%.
Clinical Effects
Potential decrease in antiretroviral efficacy
Management
Contraindicated. Use alternative agents.
Import ID
136
